Review

msd bridging-electrochemiluminescent immunoassay (eclia) (Meso Scale Diagnostics LLC)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Meso Scale Diagnostics LLC msd bridging-electrochemiluminescent immunoassay (eclia)
Msd Bridging Electrochemiluminescent Immunoassay (Eclia), supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/platform+scale/validated+bridging+electrochemiluminescent+immunoassay+method+involving+the+meso+scale+discovery+platform/pmc11368109-147-13-10
Average 90 stars, based on 1 article reviews

msd bridging-electrochemiluminescent immunoassay (eclia) - by Bioz Stars, 2026-10

90/100 stars

Images

other:

Article Title: Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection
Article Snippet: ADAs to infliximab or CT‐P13 were assessed in 5% patient serum using a validated bridging electrochemiluminescent immunoassay method involving the Meso Scale Discovery platform (MSD, Rockville, Maryland).

Article Title: Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus
Article Snippet: All samples were analysed using an in-house validated bridging electrochemiluminescent (ECL) immunoassay on the Meso Scale Discovery ® (MSD) platform as previously described [ ].

Article Title: Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
Article Snippet: Samples were probed for the presence of anti–AMG 386 binding antibodies using a validated acid-dissociation bridging electrochemiluminescent immunoassay [Meso-Scale Discovery (MSD)].

Article Title: A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx ® in Healthy Chinese Male Subjects
Article Snippet: ADA and Nabs in human serum were identified using a Meso Scale Diagnostics (MSD) bridging-electrochemiluminescent immunoassay (ECLIA) at United-Power Pharma Tech (Tianjin) Co., Ltd.

Article Title: Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
Article Snippet: ADAs to bococizumab were determined using a validated bridging electrochemiluminescent (ECL) immunoassay using MesoScale Discovery (MSD) technology and following a three-tiered testing strategy of screen, confirm specificity to bococizumab, and titer as previously described [ ].

Immunopeptidomics:

Article Title: Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
Article Snippet: .. Immunogenicity was assessed on Days 1, 29, 57 and 85 (42 days post last dose) using a validated electrochemiluminescent bridging immunoassay in human serum, using the Meso-Scale Discovery platform (Gaithersburg, Maryland, USA). ..

Electrochemiluminescence:

Article Title: Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
Article Snippet: .. The presence of anti-ABA antibodies was evaluated using validated bridging electrochemiluminescence (Meso-Scale Discovery) that differentiated between the 2 antibody specificities: immunoglobulin (Ig) and/or junction region, and T cell lymphocyte costimulation inhibitors (CTLA-4) and possibly Ig. ..